Wahlstrom Mats
SEC Form 4 insider trading activity
Wahlstrom Mats has filed 3 SEC Form 4 filings (4 transaction rows) across 2 companies, including CHRS, TLSI, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jun 9, 2026.
On the most recent filing, Wahlstrom Mats is listed as Director at TriSalus Life Sciences, Inc. Inside the rolling window, Wahlstrom Mats reported 1 open-market purchase totaling $152K in TLSI and no open-market sales.
Companies traded
Other insiders at CHRS
Insider Buying
$152K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wahlstrom Mats made?
Wahlstrom Mats has filed 3 SEC Form 4 filings (4 transaction rows) across 2 companies, including CHRS, TLSI since 2026.
Which companies does Wahlstrom Mats trade?
Wahlstrom Mats has filed SEC Form 4 disclosures for 2 companies, including CHRS, TLSI.
When was Wahlstrom Mats's most recent SEC Form 4 filing?
Wahlstrom Mats's most recent SEC Form 4 filing on Tracefour is dated Jun 9, 2026.
What is Wahlstrom Mats's total buy and sell value in the current window?
Inside the rolling retention window, Wahlstrom Mats bought $152K and sold $0 based on SEC Form 4 filings.
What was Wahlstrom Mats's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 60,000 TLSI shares on 2026-05-15, worth $152K, per SEC Form 4 filings.